UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

Date of Report: May 31, 2013

(Date of earliest event reported)

 

 

SciClone Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   0-19825   94-3116852

(State or other jurisdiction

of incorporation)

 

(Commission File

Number)

 

(IRS Employer

Identification Number)

950 Tower Lane, Suite 900, Foster

City, CA

  94404
(Address of principal executive offices)   (Zip Code)

(650) 358-3456

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) SciClone Pharmaceuticals, Inc. (the “Company”) previously announced that Gary Titus would resign from his position as Chief Financial Officer and Senior Vice President, Finance of the Company in a Form 8-K filed with the Securities and Exchange Commission on January 7, 2013. Mr. Titus tendered his resignation letter to the Company on May 31, 2013 and his final date with the Company was May 31, 2013.

Effective upon the resignation of Mr. Titus, Friedhelm Blobel, currently the Company’s President and Chief Executive Officer, will additionally serve as interim acting Chief Financial Officer of the Company until the Company appoints a new Chief Financial Officer.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 31, 2013     SCICLONE PHARMACEUTICALS, INC.
    By:  

/s/ Friedhelm Blobel

      Friedhelm Blobel
      Chief Executive Officer